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A cRiSpR activation 
and interference toolkit 
for industrial Saccharomyces 
cerevisiae strain KE6‑12
elena cámara, ibai Lenitz & Yvonne nygård*
Recent advances in CRISPR/Cas9 based genome editing have considerably advanced genetic 
engineering of industrial yeast strains. In this study, we report the construction and characterization 
of a toolkit for CRISPR activation and interference (CRISPRa/i) for a polyploid industrial yeast strain. 
In the CRISPRa/i plasmids that are available in high and low copy variants, dCas9 is expressed alone, 
or as a fusion with an activation or repression domain; VP64, VPR or Mxi1. The sgRNA is introduced 
to the CRISPRa/i plasmids from a double stranded oligonucleotide by in vivo homology‑directed 
repair, allowing rapid transcriptional modulation of new target genes without cloning. The CRISPRa/i 
toolkit was characterized by alteration of expression of fluorescent protein‑encoding genes under two 
different promoters allowing expression alterations up to ~ 2.5‑fold. Furthermore, we demonstrated 
the usability of the CRISPRa/i toolkit by improving the tolerance towards wheat straw hydrolysate of 
our industrial production strain. We anticipate that our CRISPRa/i toolkit can be widely used to assess 
novel targets for strain improvement and thus accelerate the design‑build‑test cycle for developing 
various industrial production strains.
The yeast Saccharomyces cerevisiae is one of the most commonly used microorganisms for industrial applications 
ranging from wine and beer fermentations to the production of biofuels and high-value  metabolites1,2. How-
ever, some of the current production processes are compromised by low yields and productivities, thus further 
optimization is  required3. In particular, the production of second-generation bioethanol and other biochemicals 
from lignocellulosic biomass, which provides an alternative to oil-based chemicals, suffers from sub-optimal 
 productivity4. During the hydrolysis of the raw material, inhibitory compounds (e.g. organic acids and aromatic 
aldehydes) are formed or released, compromising the microbial  performance5. While quite some work has been 
done on elucidating genes required for tolerance, much less work has been done on improving tolerance towards 
stress by altering expression of  genes6. Some previous studies demonstrated  deletion7–9 or  overexpression10–14 of 
endogenous genes to improve tolerance of S. cerevisiae towards inhibitors commonly found in lignocellulosic 
hydrolysates. However, most of the published work focuses on improving the tolerance of laboratory yeast strains 
that generally have weaker tolerance to  stress6, while translation of beneficial modifications to more robust, 
industrial strains often is very challenging. The choice of yeast strain to be engineered is crucial for the successful 
implementation of the engineered phenotype in an industrial production  process15.
Yeast strains used in industrial processes tend to be genetically diverse, since they usually arise from hybridi-
zation between different  species16. Hence, they typically present aneuploidy, polyploidy or other chromosomal 
 rearrangements16–18. This makes the strain development schemes for industrial yeast much more time-demanding 
and laborious compared to the engineering of well-studied laboratory  strains19. In order to select for superior 
strain variants, industrial production strains are often subjected to directed evolution techniques such as random 
mutagenesis, protoplast fusion or genome  shuffling20. Although these techniques are less dependent on biological 
information and available genetic tools, they suffer from being non-directional, having the risk of improving 
one trait to the detriment of  others20,21.
In recent years, CRISPR/Cas technologies have become an indispensable tool for genome editing (reviewed by 
Pickar-Oliver and  Gersbach22). These technologies are based on DNA-binding proteins (Cas endonucleases) and 
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the single guide RNA (sgRNA) duplexes that can be easily programmed to precisely target and cleave a specific 
locus on double-stranded DNA. Recent studies have shown the applicability of this technology in industrial 
yeast strains, with the simultaneous disruption of two alleles of a gene or even several genes simultaneously 
without the introduction of a selection  marker23–26. Still, the alteration of gene expression levels is often a more 
desirable metabolic engineering strategy compared to complete gene inactivation, or promoter swapping for 
 overexpression27. Dynamic gene alteration allows optimizing trade-offs between growth and  production27.
Alteration of gene expression by a nuclease-deficient form of Cas9, dCas9, often fused to an activation or 
repression domain, has been widely shown in both prokaryotes and  eukaryotes22. This so-called CRISPR activa-
tion/interference (CRISPRa/i) technology is a way to modulate the expression of genes targeted by an sgRNA, 
allowing also the expression alteration of essential genes and the manipulation of multiple traits without altering 
the target  sequence28. In laboratory yeast strains, the CRISPRa/i technology has been successfully employed to 
e.g. generate metabolic flux sensitivity  maps29, identify chemical-genetic  interactions30 and optimize different 
production  pathways31–33. CRISPR based repression (CRISPRi) has been shown using dCas9 or dCas9 fused to 
repressor domains like KRAB (Krüppel associated box) or Mxi1 (reviewed by  Jensen34). Similarly, gene activation 
by fusion of transcriptional activators, such as VP16, VP64 or VPR to dCas9 has been  reported34.
In this study, we report the construction and characterization of a set of CRISPRa/i plasmids for the altera-
tion of gene expression in a polyploid industrial yeast strain. In the CRISPRa/i plasmids, to which the sgRNA 
was introduced to its expression cassette by in vivo homology-directed repair, dCas9 was expressed alone, or as 
a fusion with an activation or repression domain (i.e. VP64, VPR or Mxi1). The CRISPRa/i toolkit was used for 
the alteration of expression of fluorescent protein-encoding genes under two different promoters. Furthermore, 
we demonstrated the usability of the CRISPRa/i system by improving the tolerance towards growth in wheat 
straw hydrolysate, by targeting SSK2, a gene essential for tolerance to environmental  stress35. We anticipate that 
our CRISPRa/i toolkit can be widely used to accelerate the design-build-test cycle for developing industrial 
production hosts.
Results
Modular design of the CRISPRa/i toolkit. In order to obtain a CRISPRa/i toolkit for transcriptional 
modulation in industrial yeast, a set of plasmids was designed for the expression of dCas9 and the sgRNA 
(Fig. 1a). The dCas9 protein was expressed alone or fused to an activation or repression domain; the mammalian 
transcriptional repressor  Mxi136, the VP64 activation domain containing 4 tandem copies of Herpes Simplex 
Viral Protein  1637 or VPR, a fusion of three different activation domains; VP64, p65, and  Rta38.
For all the CRISPRa/i plasmids, dCas9 was cloned under the strong TEF1 promoter and flanked by the SV40 
nuclear localization sequence (Fig. 1b). The sgRNA cassette consisted of the phenylalanine tRNA promoter and an 
HDV ribozyme prior to a placeholder for the sgRNA, followed by the sgRNA scaffold and an SNR52  terminator39 
(Fig. 1b). To insert the 20 bp specific sgRNA sequence targeting a gene of interest, the CRISPRa/i plasmids were 
digested at the placeholder prior to the yeast transformation. Therefore, the placeholder fragment was replaced 
by the sgRNA by in vivo homologous recombination (Fig. 1c).
In order to assess the impact of the CRISPRa/i toolkit on growth of the strains, strains expressing dCas9 or 
the dCas9-fusions (Fig. 1a) but no sgRNA were compared to a control strain carrying an empty plasmid lack-
ing any dCas9 expression cassette (Fig. 2 and Supplementary Table S1). In the strains expressing dCas9-Mxi1 
or dCas9-VPR, both the lag phase and the generation time were significantly (p < 0.05) increased compared to 
strains carrying an empty plasmid. Also the strain carrying an empty plasmid grew slightly slower than the 
parental strain (Fig. 2).
CRISPRa/i demonstration by changing expression of a fluorescence protein. An expression cas-
sette containing the red fluorescent protein-encoding gene mRuby2 under TDH3p was put into the PDR12 locus 
of the industrial strain KE6-12, a polyploid strain optimized for xylose consumption and ethanol production 
from lignocellulosic  hydrolysates40,41, resulting in a strain named KE6-12-Ruby (Supplementary Fig. S1). Dif-
ferent CRISPRa/i plasmids and sgRNAs targeting the TDH3p promoter driving mRuby2, at positions + 1 or 
− 351 bp relative to the transcription starting site (TSS), were transformed into KE6-12-Ruby and the fluores-
cence of the strains was followed over time (Fig. 3 and Supplementary Fig. S2). Whereas no change in expression 
was observed when targeting position + 1, a significant (p = 6.5E−03) downregulation of 30% was obtained at the 
end of the culture when expressing dCas9 together with the sgRNA targeting a region at − 351 bp (Fig. 3a). In 
strains expressing this sgRNA and dCas9-VPR a significant (p = 7.6E−03) increase of 144% in fluorescence was 
measured at the end of the culture (Fig. 3b). In contrast, in strains expressing dCas9-VP64 or dCas9-Mxi1 and 
the same sgRNA, no significant changes in expression were observed (Fig. 3c, d).
Characterization of the CRISPRa/i toolkit. The impact of the sgRNA target region on the transcrip-
tional modulation was evaluated using 6 different sgRNAs, targeting TDH3p at regions between − 541 and + 1 bp 
relative to the TSS (Fig. 4a). The mean fluorescence intensity (MFI) of the strains expressing mRuby2 was meas-
ured by flow cytometry from samples taken after 24 h of cultivation (Fig. 4b–e), during exponential growth 
(Supplementary Fig. S2).
In strains expressing dCas9 alone, the fluorescence of mRuby2 was significantly reduced when targeting 
positions between − 127 and − 469 bp (sg2–5, p < 0.05) (Fig. 4b), reaching a maximal decrease of 35% with sg2. 
Likewise, expression of sg2, sg3, sg4, or sg5 together with dCas9-Mxi1 led to a reduction in fluorescence (Fig. 4c). 
When targeting positions at − 127 or − 277 bp, the repression was increased by 10 or 18% in strains expressing 
dCas9-Mxi1 compared to strains expressing dCas9 alone (Fig. 4b, c). Strains expressing dCas9-VP64 and sg4 
showed a 10% increase in fluorescence compared to the no sgRNA control (Fig. 4d). In contrast, a decrease in 
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Figure 1.  Design of the CRISPRa/i toolkit for transcriptional modulation. (a) The CRISPRa/i technology 
utilizes a catalytically inactive Cas9 (dCas9) to modulate the expression of genes targeted by an sgRNA. This can 
be further increased by fusing activation or repressor domains to dCas9. (b) Schematic representation of the 
CRISPRa/i components included in the CRISPRa/i plasmids and of the sgRNA expression cassette, present in all 
the plasmids. (c) The target-specific sgRNA from a double stranded oligonucleotide (ds oligo) was inserted into 
the CRISPRa/i plasmid through in vivo homologous recombination, allowing direct phenotypic characterization 
of strains with altered gene expression.
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mRuby2 expression was obtained with sg2 and sg5. Strains expressing dCas9-VPR and sg3, sg4 or sg5 displayed 
an increase in fluorescence, with sg3 and sg4 targeting positions at − 277 or − 351 bp leading to highest activation, 
displaying an increase in fluorescence of 57% or 65%, respectively (Fig. 4e). The strain expressing dCas9-VPR 
and sg2 displayed a significant (p = 0.02) decrease in expression of mRuby2 (Fig. 4e). Strains expressing any of 
the CRISPRa/i plasmids and sgRNAs sg1 or sg6 showed no change in expression compared to the control strain 
with a placeholder in the sgRNA cassette.
Figure 2.  Growth of KE6-12-Ruby strains carrying different CRISPRa/i plasmids expressing dCas9 (blue 
solid squares), dCas9-VP64 (open turquoise circles), dCas9-Mxi1 (open yellow squares), dCas9-VPR (solid 
pink circles) or an empty plasmid lacking the dCas9 or sgRNA expression cassette (no CRISPRa/i strain, 
grey triangles). KE6-12-Ruby was added as a control to evaluate the plasmid effect (no plasmid strain, black 
triangles). The strains were grown in microbioreactors in YPD medium supplemented with geneticin for 
plasmid maintenance, and without antibiotic for the no plasmid strain. Data obtained from three biological 
replicates; shadowed regions show the standard deviation.
Figure 3.  CRISPRa/i based change in expression of a fluorescent protein, measured over time in 
microbioreactors. Normalized fluorescence of strains expressing dCas9 (a), dCas9-VPR (b), dCas9-VP64 (c) or 
dCas9-Mxi1 (d) and sgRNAs targeting a region at + 1 (sg1; red line) or − 351 (sg4; turquoise line) bp relative to 
the TSS or the CRISPRa/i plasmid with a placeholder (control; grey line). Data obtained from three biological 
replicates; shadowed regions show the standard deviation.
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To further test the applicability of the CRISPRa/i toolkit, the most effective plasmids were tested with sgR-
NAs targeting a presumably weaker  promoter42, HRK1p. In KE6-12-Ruby-Venus all native copies of HRK1 were 
replaced by a gene encoding the yellow fluorescent protein Venus (Fig. 5a and Supplementary Fig. S3). Three 
sgRNAs targeting positions at regions − 355, − 213 or − 40 bp relative to the TSS were tested, the most impactful 
being sg9, hybridizing at − 355 bp (Fig. 5b, c). The strain expressing dCas9-Mxi1 and sg9 showed a repression 
of fluorescence by 26% (Fig. 5b) whereas the strain expressing dCas9-VPR showed a 27% increase in expression 
of Venus.
High copy variants of the CRISPRa/i plasmids. In an attempt to increase the impact of the CRISPRa/i 
system, high copy variants of the CRISPRa/i plasmids expressing dCas9 or dCas9-VPR, were used for targeting 
TDH3p in the KE6-12-Ruby strain or HRK1p in the KE6-12-Ruby-Venus strain. Nonetheless, the repression 
of mRuby2 expression was similar when using centromeric, low copy (Fig. 4b) or high copy plasmids (Fig. 6a) 
Figure 4.  Modulation of mRuby2 fluorescence by different CRISPRa/i plasmids. (a) Six sgRNAs targeting 
different loci of TDH3p were tested. (b)–(e) Relative MFI of strains expressing dCas9 (b), dCas9-Mxi1 (c), 
dCas9-VP64 (d) and dCas9-VPR (e) together with either of the sgRNAs (sg1–6) or the placeholder (control). 
The box plots show the relative fluorescence, compared to KE6-12-Ruby expressing the corresponding 
CRISPRa/i plasmid with the placeholder (control, grey dashed line). Data obtained from three biological and 
three technical replicates. The line dividing the box represents the median of the data, the whiskers indicate the 
data outside the middle 50% and the outliers are shown as individual points. Statistical significance represented 
as “*” for p ≤ 0.05, “**” for p ≤ 0.01, “***” for p ≤ 0.001 and “****” for p ≤ 0.0001.
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expressing dCas9 and sg2, sg3, sg4 or sg5 (Supplementary Table S2). Similarly, expressing dCas9 and sg7, sg8 or 
sg9 from the high copy plasmid led to strains with Venus expression similar to that of the corresponding centro-
meric plasmid carrying strains (Figs. 5a, 6c and Supplementary Table S3).
CRISPRa strains expressing dCas9-VPR and sg3 or sg4 from high copy plasmids (Fig. 6b) showed a 20% 
increase in expression of mRuby2, which was a threefold lower activation compared to expressing dCas9-VPR 
and the same sgRNAs from the low copy plasmid (Fig. 4e). Conversely, strains carrying the high copy CRISPRa 
plasmid expressing dCas9-VPR and sg7, sg8 or sg9 showed an increase in expression of Venus of 29, 34 and 56%, 
respectively (Fig. 6d). Nonetheless, strains with the high copy CRISPRa plasmid expressing dCas9-VPR displayed 
a serious growth defect (Supplementary Table S1).
Application of the CRISPRa/i toolkit to improve tolerance towards lignocellulosic hydro‑
lysate. Four genes reported to be involved in tolerance towards inhibitors found in lignocellulosic hydro-
lysate, HRK143, SSK235, ISC144 and BDH245, were selected as targets for applying the CRISPRa/I toolkit. Strains 
with 3 different sgRNAs were designed for locating dCas9 or dCas9-VPR to the promoter regions of these genes 
were tested in minimal medium with added inhibitors (Supplementary Fig. S4). Strains with sgRNAs targeting 
the promoters of ISC1 or BDH2 performed the same or worse than the strain with no sgRNA (Supplementary 
Fig. S4). Two sgRNAs targeting HRK1 led to higher biomass yield whereas one of the sgRNAs tested resulted in 
a slower growth in medium supplemented with acetate (Supplementary Fig. S4). However, all strains expressing 
dCas9 and sgRNAs targeting SSK2 grew better in medium supplemented with 20 mM furfural (Supplementary 
Fig. S4) and were therefore tested in lignocellulosic hydrolysate.
Downregulation of SSK2 has previously been suggested to improve tolerance towards  furfural35. Therefore, 
targeting SSK2p with the CRISPRi system, using either dCas9 or dCas9-Mxi1 expressing plasmids were tested 
in lignocellulosic hydrolysate (Supplementary Fig. S5). The expression of dCas9-Mxi1 caused a high impairment 
on growth whereas strains expressing dCas9 alone grew comparably to the control strain or better (Fig. 7a–d).
The growth of strains expressing dCas9 from a low copy plasmid and sgRNAs targeting positions − 20, − 180 
or − 380 relative to the TSS of SSK2 (sg10, sg11 and sg12, respectively), was compared to strains expressing 
dCas9 with the placeholder (Fig. 7a–d). The generation time of all strains expressing sgRNAs targeting SSK2p 
was reduced compared to the control strain (Fig. 7a). Moreover, the strain expressing sg10 showed a 2.3-fold 
increase in final biomass yield compared to the no sgRNA control (Fig. 7b, d). The lag phase of the strains was not 
Figure 5.  Modulation of fluorescence of Venus expressed under HRK1p by CRISPRa/i. (a) Three sgRNAs 
targeting different loci of HRK1p were tested. (b)–(c) Relative MFI of strains expressing dCas9-Mxi1 (b), and 
dCas9-VPR (c) together with either of the sgRNAs (sg7–9) or the placeholder (control). The box plots show the 
relative fluorescence, compared to KE6-12-Ruby-Venus expressing the corresponding CRISPRa/i plasmid with 
the placeholder (control, grey dashed line). Data obtained from three biological and three technical replicates. 
The line dividing the box represents the median of the data, the whiskers indicate the data outside the middle 
50% and the outliers are shown as individual points. Statistical significance represented as “*” for p ≤ 0.05, “**” 
for p ≤ 0.01, “***” for p ≤ 0.001 and “****” for p ≤ 0.0001.
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affected by expression of any of the sgRNAs (Fig. 7c). When SSK2 was disrupted from KE6-12, this modification 
led to an approx. 5 h longer lag phase compared to KE6-12, when growth in hydrolysate was evaluated (Fig. 7e).
Discussion
In this study, we have successfully developed a CRISPRa/i toolkit for modulation of transcription in a polyploid, 
industrial yeast strain. The CRISPRa/i technology enables gradual modulation of gene expression allowing for 
screening of optimal expression levels. Regulation of transcription is a very sensitive balance and even small 
perturbations in gene expression can have great impact on the regulatory network and fitness of a cell subjected 
to stressful  environments46.
We evaluated our CRISPRa/i toolkit by altering the expression of fluorescent proteins expressed under the 
strong TDH3 promoter or under the relatively weak, endogenous HRK1 promoter. An increased expression 
under TDH3p was observed for two out of six sgRNAs in strains expressing dCas9-VPR from a centromeric, 
low copy plasmid (Fig. 4e). In strains expressing dCas9 alone or the dCas9-Mxi fusion two additional sgRNAs 
could decrease the expression of the fluorescent protein expressed under TDH3p (Fig. 4b, c). The most efficient 
sgRNAs, sg3 and sg4, both targeted a region of TDH3p close to a known upstream activating sequence, UAS2, 
−255 –309 bp relative to the  TSS47. The highest repression of TDH3p was found in strains expressing sg2 target-
ing position − 127 (Fig. 4c). Our results suggest that a critical regulation element could be located in this region, 
since a repression of the promoter was obtained with all the plasmids tested, including dCas9-VPR (Fig. 4b–e). 
Despite designed to function as a transcriptional activator, dCas9-VPR has also previously in combination with 
certain sgRNAs been shown to confer transcriptional  repression32.
Figure 6.  Modulation of fluorescence using high copy CRISPRa/i plasmids. (a) Relative MFI of strains 
expressing dCas9 (a), or dCas9-VPR (b) together with either of the sgRNAs targeting TDH3p (sg1–6) or HRK1p 
(sg7–9) or the placeholder (control). The box plots show the relative fluorescence, compared to KE6-12-Ruby 
(a, b) or KE6-12-Ruby-Venus (c, d) expressing the corresponding high copy CRISPRa/i plasmid with the 
placeholder (control, grey dashed line). Data obtained from three biological and three technical replicates. The 
line dividing the box represents the median of the data, the whiskers indicate the data outside the middle 50% 
and the outliers are shown as individual points. Statistical significance represented as “*” for p ≤ 0.05, “**” for 
p ≤ 0.01, “***” for p ≤ 0.001 and “****” for p ≤ 0.0001.
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Our previous work has shown that robustness and tolerance can vary greatly between industrial strains and 
evolved  mutants41,48, highlighting the need for a system that can be rapidly implemented in novel hosts. The 
benefit of plasmid-based expression of dCas9 and sgRNA in comparison with genomic integration is that the 
CRISPRa/i toolbox can rapidly be introduced to new strains and for performing novel genomic regulation events. 
Targeting a new gene and phenotyping the alteration introduced can be achieved in a week.
A recent study, where a plasmid-based CRISPRa/i-system was developed demonstrated a threefold difference 
in butanediol production when the same regulation perturbations were implemented in two different laboratory 
 yeast49. With our CRISPRa/i toolkit, a 2.5-fold change in gene expression was observed, when comparing the best 
performing sgRNA for repression using dCas9-Mxi1 with the most potent sgRNA for activation using dCas9-
VPR. This fold-change in expression level is similar to what was previously seen in laboratory yeast  strains31,32,34. 
Some previous studies report even stronger modulation of expression by CRISPRa/i, but the strength of devel-
oped CRISPRa/i systems has been shown to be largely dependent on the sgRNAs used (reviewed by  Jensen34). 
Our study confirmed that current state-of-the-art software tools fail to predict how specific sgRNAs and scRNAs 
quantitatively interfere with the activity of a native promoter. The systematic evaluation of the efficiency of dif-
ferent sgRNAs was beyond the scope of this study and as the genome sequence of KE6-12 is unknown, sequence 
variability may have a caused further decrease in targeting efficiency when targeting native promoters as was 
previously reported by Smith et al.30. Furthermore, as previous  work30,32 has shown that up to two thirds of the 
sgRNAs designed fail to function for CRISPRa/i, it may be that a higher effect of our CRISPRa/i toolkit would 
be possible by testing a larger set of sgRNAs.
In order to improve transformation efficiency and genetic stability, we chose to express the genes encoding 
the different dCas9 variants and the sgRNA from the same plasmid. The protospacer sequence of the sgRNA was 
co-transformed as a double stranded oligonucleotide and the correct assembly of the CRISPRa/i plasmids in all 
strains was confirmed by colony PCR (Supplementary Fig. S7), demonstrating that the homologous recombi-
nation capacity of our strain was remarkable. The design where the protospacer sequence is added as a double 
stranded oligonucleotide allows rapid targeting of any loci and circumvents the need for cloning when altering 
the expression of a new gene is desired. In fact, the phenotypes of the new strains can be characterized directly 
Figure 7.  Application of CRISPRi for improving growth in wheat straw hydrolysate. (a) generation time, (b) 
biomass yield and (c) lag phase of KE6-12 expressing dCas9 and different sgRNAs targeting SSK2p. (d) Growth 
of KE6-12 strain expressing dCas9 and sg10 or the placeholder. (e) Growth of KE6-12 strain compared to 
KE6-12 with SSK2 gene disrupted. The strains were grown in microbioreactors in 64% wheat straw hydrolysate 
for 50 h. Data obtained from three biological replicates (a–d) or three technical replicates (e) are expressed as 
mean ± standard deviation (SD). Statistical significance represented as “*” for p ≤ 0.05, “**” for p ≤ 0.01, “***” for 
p ≤ 0.001 and “****” for p ≤ 0.0001.
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after transformation. Similarly, during strain construction by CRISPR/Cas9 based genome editing, a highly 
efficient single-step gene disruption in the polyploid industrial strain was obtained by using marker-free donor 
DNA with 40 bp homology to the integration site. When Cas9 and the sgRNA were put on episomal plasmids, 
the plasmids could easily be cured from the yeast, effectively resulting in a marker-free, permanent modification.
High expression of Cas9 has previously been reported to be toxic for industrial  yeast26 and high expression 
of dCas9 has been shown to be toxic for many bacteria (reviewed  in50). Similarly, a few studies report that a 
high expression of the VP16 in yeast led to a slower  growth51–53. Here, we did not observe any significant growth 
defect with strains expressing dCas9, but we observed a growth defect when strains were expressing dCas9-Mxi1 
or dCas9-VPR, even without any sgRNA, (Fig. 2 and Supplementary Table S1). This effect was stronger when 
expressing the dCas9 fusions from high copy plasmids compared to when low copy plasmids were used. Still, in 
order to achieve an increase in expression under HRK1p, a higher expression of dCas9-VPR and/or the sgRNA 
appeared to be needed. In contrast, the high copy variant of the CRISPRa/i plasmids did not outperform the 
low copy plasmids when targeting TDH3p, further demonstrating that the effect of CRISPRa/i is highly target-
dependent, which emphasizes the need for a versatile CRISPRa/i toolkit. The most suited for plasmid of the 
toolkit may depend on the strain and target gene chosen.
The applicability of the developed CRISPRa/i toolkit was demonstrated by successfully improving the resist-
ance of our industrial yeast strain towards lignocellulosic hydrolysate (Fig. 7). A number of previous studies 
report engineering of resistance to phenolics, furfural and carboxylic acids, the most common inhibitors found 
in lignocellulosic hydrolysates. Still, the sensitivity towards inhibitors in hydrolysates is a major bottleneck in 
developing robust  strains4, therefore even small improvements in tolerance may have big effects on the profit-
ability of biorefineries. The MAP kinase Ssk2 has been shown to be involved in furfural  tolerance35 and it was 
also shown to be essential for combatting environmental  stress54. In our study, SSK2p was targeted with dCas9, 
resulting in an improvement in growth in wheat straw hydrolysate (Fig. 7d). When SSK2 was disrupted, growth 
was delayed (Fig. 7e), indicating that down-regulation of SSK2 is a better strategy compared to classical knock-
outs. This shows that the developed CRISPRa/i toolkit provides a rapid method for testing and validating gene 
targets for strain improvement. For industrial production strains it is likely beneficial to make the genetic targets 
identified using the CRISPRa/i toolkit stable, for instance through promoter substitution.
Collectively, this work demonstrates that CRISPRa/i can be used for transcriptional regulation in polyploid, 
industrial yeast strains. Moreover, this work has provided valuable information on transcriptional regulation 
using dCas9 and dCas9-fusions to transcriptional effectors. The CRISPRa/i plasmids have also been verified in 
laboratory CEN.PK strains (work in preparation), demonstrating that the toolkit can be expected to be widely 
applicable in different strain backgrounds. Even though there is still a need for further refining the toolkit, our 
results provide the framework for future work on CRISPRa/i based transcriptional modulation in polyploid 
yeast, accelerating the development of more robust strains to be used in biorefineries.
conclusions
The CRISPRa/i toolkit was shown to lead to transcriptional activation and repression in a polyploid yeast strain. 
The repression of a gene essential for environmental stress, SSK2, by CRISPRi demonstrated the potential of our 
toolkit for balancing and optimizing gene expression without genome editing. We anticipate that our CRISPRa/i 
toolkit can be widely used to accelerate the design-build-test cycle for developing various industrial production 
strains.
Methods
plasmid assembly. All primers and plasmids used in this study are listed in the Supplementary material 
online. Primers and oligonucleotides used were ordered from Eurofins. Phusion High-Fidelity and Phire Hot 
Start II DNA polymerases were used for PCR amplification. All PCR fragments used for plasmid assembly were 
column purified (using the GeneJET PCR Purification Kit) and sequenced (Eurofins) prior to the final assembly. 
Chemically competent Escherichia coli DH5α cells were used for cloning and transformed cells were selected on 
LB with the appropriate antibiotics. All chemicals and reagents used were purchased from ThermoScientific™ 
unless otherwise noted.
CRISPRa/i plasmids were assembled using the MoClo Yeast  Toolkit55 (Addgene #1000000061), which allows 
for rapid creation of plasmids with different selection cassettes or auxotrophic markers for expanding the versatil-
ity of the toolkit. New genetic parts containing dCas9, Mxi1, VP64 or VPR where constructed by PCR amplifica-
tion of the corresponding gene fragments from plasmids pTDH3-dCas9 (36, Addgene #46920) and pAG414GPD-
dCas9-VPR (38 Addgene #63801). The parts were put into the entry plasmid pYTK001 using overhangs added 
to the amplification primers, resulting in plasmids EC0_1_dCas9, EC0_2_dCas9_VP64, EC0_3_dCas9_Mxi1 
and EC0_4_dCas9_VPR. For the expression of the sgRNA, a placeholder sequence non-homologous to the yeast 
genome (primers hybridized by boiling followed by a gradual decrease in temperature) containing two BbsI sites 
was cloned into the plasmid #pYTK050 via BsmBI, resulting in the plasmid EC0_6_sgRNA, carrying a tRNA Phe 
promoter, the tSNR52 terminator and an HDV Ribozyme site. dCas9 was expressed under the ScTEF1 promoter 
and ScTDH1 terminator. The final multigene plasmids, EC2_1_dCas9_sgRNA, EC2_2_dCas9_VP64_sgRNA, 
EC2_3_dCas9_Mxi1_sgRNA and EC2_4_dCas9_VPR_sgRNA carried dCas9, activator/repressor domains, the 
sgRNA scaffold and the CEN6/ARS4 origin of replication. High copy plasmids EC2_7_dCas9_HC_sgRNA and 
EC2_10_dCas9_VPR_HC_sgRNA were assembled with the 2µ origin of replication.
Linear oligonucleotides with 20 nt protospacers and 40 bp overlaps on either side of the sgRNA scaffold were 
assembled into the plasmids through in vivo homologous recombination. Prior to transformation, plasmids 




Scientific RepoRtS |        (2020) 10:14605  | https://doi.org/10.1038/s41598-020-71648-w
www.nature.com/scientificreports/
For gene editing by CRISPR/Cas9, the plasmid YN2_1_Cas9 was constructed assembling several genetic ele-
ments from the MoClo Yeast Toolkit, resulting in the Cas9 gene from Streptococcus pyrogens under the ScPGK1 
promoter and terminator, the tRNA Phe promoter, tSNR52 terminator, an HDV Ribozyme site for sgRNA 
expression and the sgRNA scaffold with a bacterial GFP expression cassette replacing the protospacer. The GFP 
expression cassette was amplified from pYTK050 using primers that added flanks compatible with the MoClo 
system. In plasmids YN2_1_Cas9_Ruby and YN2_1_Cas9_Venus for genome editing, the GFP cassette was 
removed by PstI digestion and replaced with the protospacer sequences.
A description of the parts assembled for each plasmid is provided in Supplementary Tables S4–S5.
Strain construction and maintenance. The polyploid industrial S. cerevisiae strain KE6-12 was used as 
a parental strain. KE6-12 is derived from TMB400 by evolutionary engineering, with XR and XDH from Pichia 
stipitis integrated into the genome (Albers et al., unpublished). Yeast strains were transformed according to the 
Gietz  method56 and cells were selected in YPD media supplemented with G418.
KE6-12 expressing mRuby2 and Venus (KE6-12-Ruby and KE6-12-Ruby-Venus) were constructed by trans-
formation of plasmids YN2_1_Cas9_Ruby or YN2_1_Cas9_Venus and a donor DNA containing the mRuby2 or 
Venus expression cassettes (Supplementary Table S6). The fluorescence protein-encoding genes were amplified 
from EC1_10 or pYTK033, adding 40 bp homologous to the PDR12 or HRK1 locus.
Correct transformants, with pTDH3-mRuby2-tTDH1 disrupting all the PDR12 ORFs or placing Venus under 
the control of the native HRK1 promoter at all chromosome copies, were selected. All the strains were verified by 
colony PCR (Supplementary Fig. S1,S3 and Table S7) and cured for plasmids before proceeding to transcriptional 
regulation using the CRISPRa/i toolkit or tolerance assays. Deletion of PDR12 or HRK1 was during non-stressful 
conditions previously shown not affect the growth of S. cerevisiae9,57. Strains were maintained in − 80 and the 
presence of plasmids expressing dCas9 was confirmed in all the strains at the end of the growth in hydrolysate 
(Supplementary Fig. S8).
KE6-12 strain with SSK2 disrupted was constructed by co-transformation of BpiI-digested EC2_5 plasmid 
(Supplementary Table S5) and a donor DNA containing a barcode sequence with flanking 40 bp homologous 
arms to SSK2 locus (Supplementary Table S6). Correct transformants with all the SSK2 ORFs disrupted were 
selected by colony PCR (Supplementary Fig. S6).
sgRnA design. The yeast CRISPRi  webtool30 and CRISPR-ERA58 were used to design the sgRNAs, using as 
a criteria ATAC-seq values around 1 and nucleosome-free areas, to ensure accessibility to the target genes (Sup-
plementary Table S7). Additionally, poly-N and presence of off-targets were avoided and GC content between 
30 and 55 was preferred. For KE6-12-Ruby, positions at + 1, − 127, − 277, − 351, − 469 or − 541 bp relative to the 
TSS were chosen to cover most of the TDH3 promoter region. A spacing of around 200 base pairs was chosen 
to cover most of the promoter region. For KE6-12-Ruby-Venus, 3 sgRNAs were designed targeting HRK1p at 
− 41, − 213 or − 355 bp relative to the TSS, while for SSK2p positions targeting regions at − 20, − 180 or − 380 bp 
relative to the TSS were chosen. Positions for sgRNAs targeting BDH2p or ISC1p can be found in Supplemen-
tary Table S8. Verification of sgRNA integration into the expression plasmid was done by colony PCR for strains 
with sgRNAs targeting TDH3p and HRK1p (Supplementary Table S9). Oligonucleotides used as placeholder or 
sgRNA are provided in the Supplementary Table S8.
Media. The E. coli strain was grown in liquid or solid (supplemented with 15 g/L agar) Luria–Bertani (LB) 
medium (10 g/L bacto tryptone, 5 g/L yeast extract, 10 g/L NaCl) containing 25 mg/L chloramphenicol, 100 mg/L 
ampicillin or 50 mg/L neomycin. Yeast strains were grown in liquid or solid (supplemented with 15 g/L agar) 
yeast extract peptone dextrose (YPD) medium (10 g/L yeast extract, 20 g/L peptone, and 20 g/L glucose). Strains 
containing plasmids were grown on YPD medium supplemented with 200 mg/L geneticin. For the tolerance 
assays in minimal media, YNB media (1.9 g/L YNB, 0.79 g/L CSM and 5 g/L ammonium sulphate, 20 g/L glu-
cose) containing geneticin (200 mg/L) for CRISPRa/i strains and supplemented with either acetic acid (100 mM) 
furfural (20 mM) or vanillin (12 mM) was used. The medium was adjusted at pH 4.5 and buffered with succi-
nate (50 mM). For the tolerance assay in hydrolysates, wheat straw hydrolysate with a composition of 68.8 g/L 
glucose, 36.4 g/L xylose, 1.2 g/L formic acid, 4.7 g/L acetic acid, 0.6 g/L 5-(hydroxymethyl)furfural (HMF), and 
3.0 g/L  furfural45 was used. The hydrolysate was kindly provided by Dr M. Galbe at Lund University (Sweden).
culture conditions. For growth characterization and flow cytometry analysis, transformants carrying 
CRISPRa/i plasmids were grown in liquid medium using the Growth Profiler 960 platform (Enzyscreen). Pre-
cultures were inoculated from a fresh colony and incubated overnight at 30 °C and 200 rpm in YPD, and then 
transferred into 96-well, transparent bottom, white-walled plates (CR1496d, EnzyScreen) with 250 µL of YPD 
at an initial  OD600 of 0.05. Cultures were incubated at 30 °C and 250 rpm for 24 h.  OD600 values were analyzed 
using the PRECOG  software59 to extract the length of the lag phase, the generation time and the biomass  (OD600) 
yield. The average and standard deviation of three biological replicates are reported.
For real-time monitoring of mRuby2 fluorescence and growth assessment of KE6-12 in wheat straw hydro-
lysate, strains were grown in microbioreactors, using the Biolector platform (m2p-Laboratories GmbH). Precul-
tures were inoculated from a fresh colony and incubated overnight at 30 °C and 200 rpm in YPD medium in a 
96-well microtiter plate. For KE6-12-Ruby strains, overnight cultures were transferred into a 48-well microtiter 
plate (48-B FlowerPlate, m2p-labs) with 1 mL of YPD at an initial  OD600 of 0.05. For KE6-12, precultures were 
centrifuged and resuspended in sterile water to a final  OD600 of 5 and 100 µL of cell suspension was transferred 
into the 48-well microtiter plate containing 900 µL of wheat straw hydrolysate (diluted to 70%). All cultures were 
incubated at 30 °C, 1200 rpm, at a humidity of 85%. On-line parameters were measured in 20 min intervals, using 
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an excitation and emission filter at 600 nm for scattered light, with a filter gain of 10 and a filter gain of 20 for 
YPD and hydrolysate media, respectively. mRuby2 fluorescence was measured at 580/610 nm and a gain of 100.
Flow cytometry measurements. For fluorescence measurements, transformants carrying CRISPRa/i 
plasmids were grown for 24 h using the Growth Profiler, in 96-well microtiter plates containing 250 µL of YPD, 
incubated at 30 °C and 250 rpm. Fluorescence was analyzed by flow cytometry using the Guava easyCyte 8HT 
system (Merck Millipore). All samples were, prior to analysis by flow cytometry, diluted in sterile water to a final 
concentration of 200–500 cells/µL and a total amount of 5,000 cells were measured per analysis at a flow rate of 
0.59 mL/s. An excitation wavelength of 488 nm and a detection wavelength of 583 nm and 525 nm were used for 
KE6-12-Ruby and KE6-12-Ruby-Venus, respectively. The average and standard deviation of the geometric mean 
for three biological and three technical replicates is reported.
Statistical analysis. Pairwise comparisons were carried out with R, using the unpaired Student’s T-test for 
normally distributed data. The normal distribution of the data was determined using the Shapiro–Wilk test. Sta-
tistical relevance due to the p-value (P) obtained by the statistical tests performed is shown with “ns” for p > 0.05, 
“*” for p ≤ 0.05, “**” for p ≤ 0.01, “***” for p ≤ 0.001 and “****” for p ≤ 0.0001.
Data availability
All data generated or analyzed during this study are included in this published article and its supplementary 
files. Plasmids generated will be publicly available through Addgene.
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